This inventor holds 1 USPTO granted patent. Top assignee: Pharmacia Corporation. Active years: 2006.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2006
Title: The Innovative Mind of Thomas A. Wynn
Introduction: Thomas A. Wynn, an accomplished inventor based in Chicago, IL, has made significant contributions to the field of protease inhibitors through his innovative research and development. With a keen focus on the biochemical mechanisms of disease, Wynn's work addresses critical aspects of protease activity and its impact on human health.
Latest Patents: Thomas A. Wynn holds a notable patent titled "Piperidinyl- and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors." This invention targets proteinase inhibitors and specifically centers on hydroxamic acids that inhibit matrix metalloproteinase (MMP) and aggrecanase activity. The patent details the synthesis of these compounds, their structural formula, and their potential therapeutic applications in treating conditions associated with MMP and aggrecanase activity. The innovation represents an important advancement in the development of treatments for various pathological conditions.
Career Highlights: Throughout his career, Thomas A. Wynn has been affiliated with the Pharmacia Corporation, where he has utilized his expertise in the pharmaceutical industry to drive research breakthroughs. His dedication to innovation and his ability to translate complex scientific concepts into practical solutions have set him apart as a leading figure in his field.
Collaborations: In his pursuit of innovation, Wynn has collaborated with notable colleagues such as Thomas E. Barta and Daniel Paul Becker. This collaborative spirit reflects a commitment to leveraging diverse expertise to enhance research outcomes and push the boundaries of scientific understanding.
Conclusion: Thomas A. Wynn exemplifies the innovative spirit that drives advancements in biomedical research. With his significant patent portfolio and collaborations, he continues to make an impact in the realm of protease inhibitors and related therapeutic modalities. His contributions not only advance scientific knowledge but also hold promise for improving health outcomes for patients affected by various conditions.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile